Antiva to tweak dosing of HPV drug, seek funding for new trial following mixed early data

Antiva Biosciences said one of two regimens of its candidate for human papillomavirus (HPV) has yielded positive results in women with a high-risk, persistent form of the infection. The antiviral drug produced a higher rate ...